Statin-induced necrotizing autoimmune myopathy: a systematic review

IF 1.4 Q3 RHEUMATOLOGY
M. Somagutta, N. Shama, M. K. Pormento, R. Jagani, N. Ngardig, Klodin Ghazarian, Greta Mahmutaj, Khaled El-Faramawy, Ashwini Mahadevaiah, M. Jain
{"title":"Statin-induced necrotizing autoimmune myopathy: a systematic review","authors":"M. Somagutta, N. Shama, M. K. Pormento, R. Jagani, N. Ngardig, Klodin Ghazarian, Greta Mahmutaj, Khaled El-Faramawy, Ashwini Mahadevaiah, M. Jain","doi":"10.5114/reum.2022.114108","DOIUrl":null,"url":null,"abstract":"Statins are a class of lipid-lowering medications used worldwide by millions of people and are safe for frequent use in most patients. However, they cause necrotizing autoimmune myopathy in some patients. We reviewed case reports of 80 patients from 2010 to present diagnosed with statin-induced necrotizing autoimmune myopathy (SINAM), aiming to analyze the clinical, physiological, serologic characteristics and outcomes of SINAM. The mean age of these patients was 66 ±9.4, the majority being male (61.3%). All patients reported proximal muscle weakness, and a few had myalgias, extra muscular symptoms such as dysphagia, and pulmonary complications. Most of the patients were on atorvastatin, simvastatin, or rosuvastatin. The mean creatine kinase was 10,094.2 ±7,351.7 U/l, and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme was positive for 93.8% of patients. The majority of patients were started on steroids; other treatments were also used. Prompt cessation of statins and initiation of immunosuppressants reduced morbidity and mortality.","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"21 1","pages":"63 - 69"},"PeriodicalIF":1.4000,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/reum.2022.114108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Statins are a class of lipid-lowering medications used worldwide by millions of people and are safe for frequent use in most patients. However, they cause necrotizing autoimmune myopathy in some patients. We reviewed case reports of 80 patients from 2010 to present diagnosed with statin-induced necrotizing autoimmune myopathy (SINAM), aiming to analyze the clinical, physiological, serologic characteristics and outcomes of SINAM. The mean age of these patients was 66 ±9.4, the majority being male (61.3%). All patients reported proximal muscle weakness, and a few had myalgias, extra muscular symptoms such as dysphagia, and pulmonary complications. Most of the patients were on atorvastatin, simvastatin, or rosuvastatin. The mean creatine kinase was 10,094.2 ±7,351.7 U/l, and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme was positive for 93.8% of patients. The majority of patients were started on steroids; other treatments were also used. Prompt cessation of statins and initiation of immunosuppressants reduced morbidity and mortality.
他汀类药物诱导的坏死性自身免疫性肌病:一项系统综述
他汀类药物是全球数百万人使用的一类降脂药物,对大多数患者来说是安全的。然而,它们在一些患者中引起坏死性自身免疫性肌病。我们回顾了2010年至今诊断为他汀类药物诱导的坏死性自身免疫性肌病(SINAM)的80例病例报告,旨在分析SINAM的临床、生理、血清学特征和转归。患者平均年龄66±9.4岁,男性居多(61.3%)。所有患者均报告近端肌肉无力,少数患者有肌痛、肌肉外症状,如吞咽困难和肺部并发症。大多数患者服用阿托伐他汀、辛伐他汀或瑞舒伐他汀。肌酸激酶平均值为10094.2±7351.7 U/l,抗3-羟基-3-甲基戊二酰辅酶A还原酶阳性的占93.8%。大多数患者开始使用类固醇;还使用了其他治疗方法。及时停用他汀类药物并开始使用免疫抑制剂可降低发病率和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reumatologia
Reumatologia Medicine-Rheumatology
CiteScore
2.70
自引率
0.00%
发文量
44
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信